Public Employees Retirement System of Ohio Purchases New Holdings in Illumina, Inc. $ILMN

Public Employees Retirement System of Ohio acquired a new position in shares of Illumina, Inc. (NASDAQ:ILMN) during the 2nd quarter, Holdings Channel.com reports. The fund acquired 44,725 shares of the life sciences company’s stock, valued at approximately $7,864,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Capital World Investors lifted its holdings in shares of Illumina by 0.6% during the fourth quarter. Capital World Investors now owns 20,101,173 shares of the life sciences company’s stock valued at $2,636,483,000 after purchasing an additional 124,323 shares during the last quarter. BlackRock Inc. purchased a new stake in shares of Illumina in the 2nd quarter worth approximately $3,374,423,000. State Street Corp grew its stake in shares of Illumina by 3.2% in the 4th quarter. State Street Corp now owns 6,190,114 shares of the life sciences company’s stock worth $811,895,000 after buying an additional 190,324 shares during the last quarter. WCM Investment Management LLC grew its stake in shares of Illumina by 45.5% in the 1st quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock worth $715,579,000 after buying an additional 1,851,848 shares during the last quarter. Finally, AQR Capital Management LLC increased its position in Illumina by 30.3% during the 4th quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company’s stock valued at $580,531,000 after buying an additional 1,028,099 shares in the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Insider Buying and Selling

In other news, insider Scott M. Davies sold 615 shares of the firm’s stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $200.00, for a total transaction of $123,000.00. Following the sale, the insider owned 20,338 shares of the company’s stock, valued at $4,067,600. This trade represents a 2.94% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 138,379 shares of Illumina stock in a transaction that occurred on Thursday, August 27th. The stock was sold at an average price of $228.89, for a total transaction of $31,673,569.31. Following the completion of the sale, the director owned 1,033,910 shares of the company’s stock, valued at $236,651,659.90. This represents a 11.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 1,799,688 shares of company stock worth $379,517,231. 2.90% of the stock is owned by corporate insiders.

Illumina Stock Performance

Shares of ILMN opened at $207.13 on Wednesday. The business’s fifty day simple moving average is $195.94 and its two-hundred day simple moving average is $157.18. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53. Illumina, Inc. has a 12 month low of $88.00 and a 12 month high of $231.81. The company has a market cap of $31.28 billion, a price-to-earnings ratio of 38.64, a P/E/G ratio of 3.01 and a beta of 1.46.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.08. The firm had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The company’s revenue was up 9.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Research analysts anticipate that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have issued reports on ILMN shares. Piper Sandler reiterated an “overweight” rating and set a $225.00 price objective (up from $200.00) on shares of Illumina in a research note on Monday, August 3rd. TD Cowen raised their price target on Illumina from $192.00 to $210.00 and gave the company a “hold” rating in a report on Friday, July 31st. Guggenheim lifted their price target on Illumina from $200.00 to $226.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Sanford C. Bernstein reiterated a “market perform” rating and issued a $215.00 price target on shares of Illumina in a research note on Friday, July 31st. Finally, Stifel Nicolaus increased their price objective on shares of Illumina from $155.00 to $225.00 and gave the company a “buy” rating in a research report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $188.40.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.